(Q44451164)

3 December 2017

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity (English)

1 reference

3 December 2017

7

Isaac Ben-Bassat

1 reference

3 December 2017

4

Izhar Hardan

1 reference

3 December 2017

8

Arnon Nagler

1 reference

3 December 2017

1

Avichai Shimoni

1 reference

3 December 2017

Bella Bielorai

2

1 reference

3 December 2017

Amos Toren

series ordinal

3

1 reference

3 December 2017

Abraham Avigdor

series ordinal

5

1 reference

3 December 2017

Moshe Yeshurun

series ordinal

6

1 reference

3 December 2017

1 May 2003

1 reference

3 December 2017

Experimental Hematology

1 reference

3 December 2017

31

1 reference

3 December 2017

5

1 reference

3 December 2017

428-434

1 reference

Bone-marrow transplantation (first of two parts).

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

The role of busulfan in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Venoocclusive disease of the liver following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900047-X

7 January 2021

10.1016/S0301-472X(03)00047-X

Identifiers

DOI

1 reference

3 December 2017

1 reference